These results come from Intensity Therapeutics’ Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer that haven’t been treated with chemotherapy. The big news here is the company seeing tumor cell necrosis and immunomodulatory effects from this study.
Angel Arnaout, Breast Surgical Oncologist at the Ottawa Hospital, said the following about the clinical trial data:
“The ability for INT230-6 to induce necrosis and noted immune effects prior to a patient’s surgery, while maintaining a favorable safety profile, would be a major move forward for the treatment paradigm of breast cancer and potentially many other cancers.”
What’s Next for INTS Stock?
Considering the positive results from this clinical trial, Intensity Therapeutics is already considering a Phase 3 study of INT230-6. The company also believes there’s potential for INT230-6 to act as a treatment for other forms of cancer.
With all of this news comes heavy trading of INTS stock. As of this writing, more than 23 million shares have changed hands. That’s a massive surge in trading volume compared to its daily average of only about 16,00 shares.
INTS stock is up 132.5% as of Friday morning.
Investors can find more of the latest stock market news ready to go at the following links!
We’ve got all of the latest stock market news for Friday. Among that is what’s moving Hello Group (NASDAQ:MOMO), Johnson Outdoors (NASDAQ:JOUT) and Spotify (NYSE:SPOT) stock today. You can find all of that info at the following links!
More Stock Market News for Friday
- MOMO Stock Earnings: Hello Gr Beats EPS, Misses Revenue for Q3 2023
- JOUT Stock Earnings: Johnson Outdoors Misses EPS, Misses Revenue for Q4 2023
- SPOT Stock Alert: What to Know as Spotify CFO Steps Down
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.